[1]徐勇平.舒肝宁注射液治疗晚期血吸虫病肝纤维化的效果及其对血清指标的影响[J].医学信息,2020,33(24):151-153.[doi:10.3969/j.issn.1006-1959.2020.24.043]
　XU Yong-ping.Shuganning Injection in the Treatment of Advanced Schistosomiasis Liver Fibrosis and Its Influence on Serum Indexes[J].Medical Information,2020,33(24):151-153.[doi:10.3969/j.issn.1006-1959.2020.24.043]
点击复制

舒肝宁注射液治疗晚期血吸虫病肝纤维化的效果及其对血清指标的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年24期
页码:
151-153
栏目:
中医中药
出版日期:
2020-12-15

文章信息/Info

Title:
Shuganning Injection in the Treatment of Advanced Schistosomiasis Liver Fibrosis and Its Influence on Serum Indexes
文章编号:
1006-1959（2020）24-0151-03
作者:
徐勇平
湖口县血吸虫病防治站预防科，江西 湖口 332500
Author(s):
XU Yong-ping
Prevention Department,Schistosomiasis Control Station,Hukou 332500,Jiangxi,China
关键词:
舒肝宁注射液; 晚期; 血吸虫病; 肝纤维化; γ-干扰素
Keywords:
Shuganning injection; Advanced stage; Schistosomiasis; Liver fibrosis; γ-interferon
分类号:
R575.5
DOI:
10.3969/j.issn.1006-1959.2020.24.043
文献标志码:
A
摘要:
目的 研究舒肝宁注射液治疗晚期血吸虫病肝纤维化治疗效果。方法 选取2018年8月~2020年8月在我站诊治的70例晚期血吸虫病肝纤维化患者为研究对象，采用随机数字表法分为对照组和观察组，各35例。对照组采用常规治疗，观察组在对照组治疗基础上给予舒肝宁注射液治疗，比较两组临床治疗总有效率、肝功能指标、肝纤维化指标、转化生长因子β1、γ-干扰素水平及临床不良反应发生情况。结果 观察组治疗总有效率为91.42%，高于对照组的80.00%（P＜0.05）；治疗后两组ALT、AST、TBIL均低于治疗前，且观察组低于对照组（P＜0.05）；治疗后两组HA、IV-C、LN、PC-Ⅲ均低于治疗前，且观察组低于对照组（P＜0.05）；治疗后两组TGF-β1均低于治疗前，IFN-γ均高于治疗前，且观察组TGF-β1低于对照组，IFN-γ高于对照组（P＜0.05）；观察组不良反应发生率5.71%与对照组8.57%比较（P＞0.05）。结论 舒肝宁注射液可提高晚期血吸虫病肝纤维化患者临床治疗总有效率，改善肝功能，降低肝纤维化指标，降低血清转化生长因子β1，提高γ-干扰素水平，且临床不良反应少，应用安全可靠。
Abstract:
Objective To study the therapeutic effect of Shuganning injection in the treatment of advanced schistosomiasis liver fibrosis.Methods A total of 70 patients with advanced schistosomiasis liver fibrosis diagnosed and treated in our station from August 2018 to August 2020 were selected as the research objects. They were divided into the control group and the observation group by random number table, with 35 cases in each group. The control group was treated with conventional treatment, and the observation group was treated with Shuganning injection based on the treatment of the control group. The total effective rate of clinical treatment, liver function indexes, liver fibrosis indexes, transforming growth factor β1 and γ-interferon levels were compared between the two groups and the occurrence of clinical adverse reactions.Results The total effective rate of treatment in the observation group was 91.42%, which was higher than 80.00% in the control group (P＜0.05); after treatment, the ALT, AST and TBIL of the two groups were lower than before treatment, and the observation group was lower than the control group (P＜0.05); After treatment, HA, IV-C, LN, PC-Ⅲ in the two groups were lower than before treatment, and the observation group was lower than the control group (P＜0.05); after treatment, TGF-β1 in both groups was lower than before treatment, IFN -γ was higher than before treatment, and TGF-β1 in the observation group was lower than that in the control group, and IFN-γ was higher than that in the control group (P＜0.05); the incidence of adverse reactions in the observation group was 5.71% compared with 8.57% in the control group (P＞0.05).Conclusion Shuganning injection can increase the total effective rate of clinical treatment of patients with advanced schistosomiasis liver fibrosis, improve liver function, reduce liver fibrosis indicators, reduce serum transforming growth factor β1, increase γ-interferon level, and have fewer clinical adverse reactions,the application is safe and reliable.

参考文献/References:

[1]牛长生,余永辉.晚期血吸虫病肝硬化患者凝血功能检测分析[J].热带病与寄生虫学,2014,12(2):81-82. [2]Miao L,Qingsi W,Peng C,et al.A Boswellic Acid-Containing Extract Ameliorates Schistosomiasis Liver Granuloma and Fibrosis through Regulating NF-κB Signaling in Mice[J].PLoS One,2014,9(6):e100129. [3]宣爱林,尤璐,蒋卫东.丹参酮ⅡＡ磺酸钠治疗晚期血吸虫病效果[J].中国血吸虫病防治杂志,2014,26(2):224-225. [4]宋兰桂,吴忠道.日本血吸虫病肝纤维化的病理学及发病机制研究进展[J].中国血吸虫病防治杂志,2015,27(2):213-216. [5]赵红建,诸葛毅,骆利康,等.血吸虫病患者肝纤维化的病理变化与超微结构观察[J].中华地方病学杂志,2015,34(2):109-111. [6]王瑜,夏超明.可诱导共刺激分子/可诱导共刺激分子配体信号通路对血吸虫肝纤维化的影响[J].中华传染病杂志,2015,33(2):96-101. [7]项凤梅,江一平.益气活血法治疗腹水型晚期血吸虫肝病40例[J].陕西中医,2015,36(10):1342-1343. [8]Huang LH,Qiu YW,Hua HY,et al.The efficacy and safety of en?tecavir in patients with advanced schistosomiasis co?infected with hepatitis B virus[J].International Journal of Infectious Diseases,2014,17(8):E606-E609. [9]谢园园,徐元宏,储德勇,等.巨噬细胞在血吸虫病肝纤维化过程中的作用研究进展[J].中国血吸虫病防治杂志,2015,27(6):669-667. [10]葛华阶,白定华,夏晓玲,等.软肝丸治疗血吸虫病肝纤维化的效果[J].中国血吸虫病防治杂志,2014,4(2):197-199,202. [11]刘忠政,梁洁萍,聂怡初,等.复方血栓通胶囊基于血液循环和凝血过程相关靶点的网络药理学研究[J].中山大学学报(自然科学版),2014,52(2):97-100. [12]Hua HY,Yin AH,Xu MH,et al.Advanced schistosomiasis reappeared after curing seemingly being cured for over 20 years and without known history of reexposure to Schistosoma japonicum[J].Parasitol Res,2015,114(9):3535-3538. [13]朱永辉,邓维成,何永康,等.舒肝宁注射液对晚期血吸虫病肝纤维化患者血清转化生长因子β１、γ-干扰素水平的影响[J].中国老年学杂志,2014,32(8):1592-1593. [14]徐倩,黄海.丹参酮ⅡA磺酸钠治疗日本血吸虫病肝纤维化的长期效果[J].中国热带医学,2016,16(12):1216-1219. [15]肖海青.马洛替酯治疗晚期血吸虫病30例临床观察[J].中国民族民间医药,2014,22(10):82-84.

相似文献/References:

[1]胡平华,黄 勤,李志华.含卡培他滨方案一线或后线治疗晚期乳腺癌的效果对比[J].医学信息,2018,31(22):142.[doi:10.3969/j.issn.1006-1959.2018.22.041]
　HU Ping-hua,HUANG Qin,LI Zhi-hua.Comparison of the Efficacy of Capecitabine Regimen in the Treatment of Advanced Breast Cancer with First-line or Posterior Line Therapy[J].Medical Information,2018,31(24):142.[doi:10.3969/j.issn.1006-1959.2018.22.041]
[2]李 博.紫杉醇加顺铂治疗晚期老年非小细胞癌的疗效[J].医学信息,2020,33(10):153.[doi:10.3969/j.issn.1006-1959.2020.10.045]
　LI Bo.Paclitaxel Plus Cisplatin in the Treatment of Advanced Elderly Non-small Cell Carcinoma[J].Medical Information,2020,33(24):153.[doi:10.3969/j.issn.1006-1959.2020.10.045]
[3]黄定蒙.不同等级医院晚期胃肠恶性肿瘤治疗效果及生活质量比较[J].医学信息,2023,36(02):127.[doi:10.3969/j.issn.1006-1959.2023.02.026]
　HUANG Ding-meng.Comparison of Treatment Effect and Quality of Life of Advanced Gastrointestinal Malignant Tumors in Different Grade Hospitals[J].Medical Information,2023,36(24):127.[doi:10.3969/j.issn.1006-1959.2023.02.026]

更新日期/Last Update: 1900-01-01